^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Colon Cancer
    Drug:gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor) +
    mirdametinib (PD-0325901) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

    Excerpt:
    When PKI-587 and PD0325901 (100 nmol/L) were combined, increased caspase 3/7 activity was detected (Supplementary Fig. S5B) and cPARP was induced at 30 nmol/L or more PKI-587...Against small HCT116 tumor xenografts (∼300 mm3) either PKI-587 (25 mg/kg) or PD0325901 (50 mg/kg) alone (day 1, 5, 9 regimen) were ineffective (Fig. 4D). In combination, statistically significant (P < 0.01) antitumor efficacy was observed.
    DOI:
    10.1158/1078-0432.CCR-10-1694